Coeptis Therapeutics Holdings Inc美股招股说明书(2026-04-17版)

Filed pursuant to Rule 424(b)(3)Under the Securities Act of 1933 in connection withRegistration Statement No. 333-288329 PROSPECTUS SUPPLEMENT NO. 2To Prospectus Dated January 5, 2026 COEPTIS THERAPEUTICS HOLDINGS, INC. This Supplement No. 2 (this “Supplement”) supplements the proxy statement/prospectus of Coeptis Therapeutics Holdings, Inc. (the“Company” or “Coeptis”) dated January 5, 2026 (as supplemented or amended from time to time, the “Prospectus), which forms a partof the Registration Statement on Form S-4 (File No. 333-288329) declared effective by the Securities and Exchange Commission (the“SEC”) on December 23, 2025 (the “Registration Statement”). Capitalized terms used herein, but not otherwise defined, shall have themeanings ascribed to such terms in the Prospectus. This Supplement is being filed to supplement the information included in the Prospectus with information contained in our AnnualReport on Form10-K filed with the SEC on March 19, 2026, which is set forth below. To the extent information in this Supplementdiffers from, updates or conflicts with information contained in the Prospectus, the information in this Supplement is the more currentinformation. This Supplement is not complete without the Registration Statement. This Supplement should be read in conjunction with, and maynot be delivered or utilized without, the Registration Statement. This Supplement is qualified by reference to the RegistrationStatement, except to the extent that the information in this Supplement supersedes the information contained in the RegistrationStatement. You should read the Prospectus, this Supplement and any additional prospectus supplement or amendment carefully before you investin our securities. We are a “smaller reporting company” under applicable federal securities laws and will be subject to reduced public companyreporting requirements for so long as we remain a smaller reporting company. Investing in our securities involves a high degree of risk. Before buying any securities, you should carefully read the discussionof the risks of investing in our securities in “Risk Factors”beginning on page 43 of the Prospectus and any other risk factorscontained in any applicable prospectus supplement and in the documents incorporated by reference herein and therein. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of thesecurities to be issued under this prospectus or determined if this prospectus is truthful or complete. Any representation to thecontrary is a criminal offense. The date of this prospectus supplement is April 17, 2026. UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 FORM 10-K (Mark One)☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 Or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number: 001-39669 Coeptis Therapeutics Holdings, Inc.(Exact name of registrant as specified in its charter) Delaware98-1465952(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.) 105 Bradford Rd, Suite 420Wexford, Pennsylvania 15090(Address of Principal Executive Offices) (Zip Code) (Registrant’s Telephone Number, Including Area Code):(724) 934-6467 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes☐No☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes☐No☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorterperiod that the registrant was required to submit such files.) Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒ Large accelerated filer☐Non-accelerated filer☒Emerging growth company☒ If an emerging growth company, indicate by a check mark if the registrant has elected not